The group's principal activity is to develop and produce commercial anti-body based cancer therapeutics and other pharmaceuticals based on molecular immunology. A preclinical testing of a second tumor-activated prodrugs candidate, hun901-dm1 is conducted for the treatment of small-cell lung cancer. The product candidates of the group are tumor-activated prodrugs or taps which are based on proprietary technology platform that combines monoclonal antibodies that targets tumor cells and potent drugs.
